Good Manufacturing Practices (GMP): The Complete 2026 Compliance & Certification Guide

Good Manufacturing Practices (GMP) form the regulatory foundation for every safe, effective medicine on the market. As PIC/S grows to 57 member authorities and FDA pilots its Quality Management Maturity program, what counts as “compliant” in 2026 is evolving fast. This guide explains what GMP and cGMP require, how to get certified, and what to look for in a GMP-compliant manufacturing partner.

What Is GMP?

GMP is the regulatory framework that governs how medicines are produced, tested, and released to ensure every batch is safe, effective, and consistent. Non-compliance can trigger recalls, import bans, or facility shutdowns.

Market Overview: GMP Pharmaceutical Manufacturing Demand Is Accelerating

According to Global Market Insights (2026), the global pharmaceutical CDMO market reached $173.7 billion in 2025 and is projected to grow from $184.9 billion in 2026 to $342 billion by 2035, a 7.1% compound annual growth rate. A narrower slice of that market contract pharmaceutical manufacturing specifically is estimated at $255.74 billion in 2026, growing to $501.55 billion by 2033 at a 10.1% CAGR, according to Coherent Market Insights (2026). Both trajectories point to the same conclusion: as outsourcing deepens, GMP compliance capability is becoming a primary differentiator between CDMOs, not a baseline assumption.

Three macro trends are shaping this space heading into 2026:

• Owners remain accountable for contract facility failures. FDA guidance states that an owner remains responsible for CGMP compliance even when a quality agreement assigns a manufacturing activity to a contract facility, and that this responsibility cannot be delegated away. In practice, a CDMO’s compliance lapse can still trigger regulatory action against the sponsor, a key consideration for buyers evaluating outsourcing risk.
• Data integrity remains the dominant citation driver. Industry analyses consistently find that 60–80% of GMP warning letters include data integrity findings as a contributing factor.
• AI governance has entered GMP enforcement. FDA issued its first warning letter citing AI misuse as a GMP breach in April 2026, after a company’s AI agents drafted cGMP specifications and records without human review.

At the 2026 ISPE European Annual Conference, EMA confirmed active revision of EU GMP guidance, particularly Chapter 4, Annex 11, and the new AI-focused Annex 22.

In practice, quality leaders are already living this shift. Speaking on the PharmaSource podcast, Ingrid Lux, Lead Quality Disposition in Oncology & Small Molecule External Supply Europe at Takeda, described how quality systems evolved over the borders of the own organisation as pharma consolidated, forcing quality teams to coordinate across different organizational cultures rather than overseeing a single site directly. On the growing role of AI in quality decisions, she cautioned that human expertise remains essential to judge whether the data a system produces is actually consistent and trustworthy.

Latest GMP News-

5P’s of Good Manufacturing Practice (GMP)

Good Manufacturing Practice is the set of regulations, guidelines, and quality systems that ensure pharmaceutical products are consistently manufactured and controlled to defined quality standards, from raw material intake through finished product release.

Who needs GMP?

Pharmaceuticals carry the strictest requirements, but the same core discipline applies to medical devices, dietary supplements, cosmetics, and food manufacturing, each governed by its own regulatory code (for example, 21 CFR 210/211 for drugs, 21 CFR 111 for supplements). GMP is also one of eight related disciplines in the broader “GxP” family, which includes Good Clinical Practice (GCP), Good Laboratory Practice (GLP), and Good Distribution Practice (GDP), among others, according to PharmaSource’s guide to Good Clinical Practice.

Relevant across every drug category, though complexity scales with modality. Small-molecule generics and APIs follow well-established pathways (ICH Q7). Biologics, cell and gene therapies, and other ATMPs carry materially higher complexity, since small-batch production leaves little margin for error.

A Brief History of GMP

GMP as a formal regulatory concept traces back to the U.S. Federal Food, Drug, and Cosmetic Act (1938) and was sharpened significantly by the 1962 Kefauver-Harris Amendment, passed in response to drug safety failures that exposed the risks of unregulated manufacturing. The WHO adopted its own GMP guidelines in the 1960s and 1970s to support international harmonization, and today more than 100 countries base their national frameworks on WHO’s standard.

cGMP vs. GMP

	GMP	cGMP
Definition	Baseline regulatory framework	Ongoing obligation to use current systems and methods
Enforced by	Multiple agencies globally	Specifically the term used by FDA
Key implication	Fixed requirements	A facility can be “GMP-compliant on paper” yet still draw criticism if systems have fallen behind current practice

The terms are often used interchangeably, but there’s a meaningful distinction. GMP describes the baseline regulatory framework: the fixed set of requirements a manufacturer must meet. Current Good Manufacturing Practices (cGMP) adds an ongoing obligation that manufacturers continuously adopt current systems, equipment, and methods rather than relying on outdated approaches simply because they were once compliant.

In 2026, this gap shows up most often around data integrity and electronic records, legacy systems that were compliant when installed but have not kept pace with “current” expectations.

GMP vs. ISO 9001

	GMP	ISO 9001
Scope	Product-specific: pharmaceuticals, food, devices	Generic quality management, any industry
Mandatory?	Legally required to sell regulated products	Voluntary certification
Enforced by	Government regulators (FDA, EMA, WHO)	Independent certification bodies
Focus	Patient and consumer safety outcomes	Process consistency and customer satisfaction

Many manufacturers hold both. ISO 9001 provides the quality management backbone, while GMP adds product-specific, legally mandated controls on top. PharmaSource’s Pharma Supply Chain guide similarly frames ISO 9001 as the quality management system framework that sits alongside GMP and GDP requirements across the supply chain.

Global GMP Regulatory Landscape

Authority	Region	Key Mechanism
FDA	United States	cGMP under the FD&C Act; Form 483s, warning letters, import alerts
EMA	European Union	Manufacturing Authorisation, Qualified Person (QP) sign-off, GDP standards
WHO	100+ countries	Global GMP guidelines; Certificate of Pharmaceutical Product (CPP)
PIC/S	57 member authorities	Harmonizes inspection standards across borders

PIC/S in 2026: Jordan’s JFDA became the 57th PIC/S Participating Authority on January 1, 2026, with China, Ghana, Kazakhstan, and the Philippines in pre-accession (PIC/S, 2026; DDReg Pharma, 2026). For sponsors vetting CDMOs in emerging markets, PIC/S membership of the local regulator is a useful proxy for inspection rigor.

The 10 Fundamental Principles of GMP

1. Create Standard Operating Procedures (SOPs)
2. Enforce SOPs and work instructions
3. Document procedures and processes
4. Validate the effectiveness of SOPs
5. Design and use working quality systems
6. Maintain systems, facilities, and equipment
7. Develop job competence of workers
8. Prevent contamination through cleanliness
9. Prioritize quality and integrate it into workflow
10. Conduct GMP audits regularly

Good Manufacturing Practices (GMP) Certification

Pharma certification works differently from food or cosmetics certification. There is no single third-party body issuing one universal “GMP certificate.”

Region	How compliance is verified
EU	National competent authority inspects and issues a formal GMP certificate, published on EudraGMDP
WHO markets	A Certificate of Pharmaceutical Product (CPP) confirms GMP compliance for export
United States	No certificate. FDA records an inspection classification (NAI, VAI, or OAI) in its public databases

Step	What happens
1. Gap assessment	Benchmark current operations against the applicable GMP code
2. Implementation	Update facility and process controls, premises, and equipment
3. Documentation	Build out SOPs, batch records, and specifications
4. Training	Staff competency and change-control training
5. Internal audit	Mock audit to confirm readiness

Timeline: typically 6 to 12 months for pharmaceutical manufacturing, given more extensive validation requirements than food or supplement GMP. EU GMP certificates are generally valid for three years before a renewal inspection is required.

FDA’s Quality Management Maturity (QMM) Program

Beyond baseline cGMP, FDA is piloting a voluntary program that rates manufacturers on practices exceeding minimum requirements: management commitment, technical excellence, and continuous improvement culture. FDA opened its third QMM assessment cohort in February 2026, alongside new risk-based inspection compliance programs published in April and June 2026 (FDA, 2026). For sponsors, a CDMO’s participation, even at pilot stage, signals quality maturity beyond a clean inspection record alone.

Manufacturing Considerations for Good Manufacturing Practice (GMP)

Facility qualification status, data integrity maturity, technology transfer track record, and quality culture all determine whether a site holds up under real regulatory scrutiny.

Technology transfer is one of the highest-risk moments in outsourcing. Equipment differences, raw material variability, and scale changes can all introduce deviations. A CDMO’s documented transfer track record often predicts future performance better than certifications alone.

Contamination control and process validation remain the other major pillars. FDA inspectors increasingly expect mature, continued process verification programs rather than one-time validation studies.

Quality oversight across a supplier network is its own discipline. In a PharmaSource podcast episode, Stephanie Gaulding, Managing Director at Pharmatech Associates, explains that robust quality oversight plans are central to both successful supplier relationships and cost reduction in pharmaceutical manufacturing, a point that reinforces why the CDMO selection criteria below matter as much as the certification itself.

What Drives, and Slows, GMP Adoption

Growth drivers accelerating GMP-compliant manufacturing demand include:

• Rising outsourcing of both drug substance and drug product manufacturing to specialized CDMOs
• Expansion of biologics, cell and gene therapy, and other advanced therapy pipelines requiring specialized GMP infrastructure
• Growing regulatory harmonization efforts across FDA, EMA, and WHO reducing duplicative compliance burden for global manufacturers
• Increased sponsor demand for CDMOs with proven inspection track records as outsourcing risk becomes a board-level concern

Growth inhibitors specific to GMP compliance and scale-up include:

• Persistent labor shortages and skills gaps in quality and manufacturing roles
• Intellectual property risk inherent in outsourcing proprietary manufacturing processes to third parties
• High capital costs of facility upgrades and qualification, which disproportionately burden smaller and mid-tier manufacturers
• Escalating compliance overhead for CDMOs managing multiple client programs across shared, multi-product facilities

Key Criteria for Selecting a GMP-Compliant CDMO Partner

Selecting the right manufacturing partner requires evaluation across several dimensions simultaneously, since strength in one area rarely compensates for weakness in another:

• Current certifications and inspection history — verify active FDA, EMA, and relevant national authority approvals, and request the facility’s Form 483 and warning letter history directly rather than relying on self-reported summaries
• Data integrity and electronic systems maturity — given that data integrity issues drive the majority of warning letters, assess whether audit trails are not just generated but actively reviewed
• Technology transfer track record — request case studies or references demonstrating successful transfer of processes similar in complexity to your product
• Facility and equipment qualification status — confirm current IQ/OQ/PQ documentation and ask when equipment was last requalified
• Pharmaceutical quality management system maturity — a functioning CAPA process and closed-loop deviation resolution are stronger signals of quality culture than documentation that issues were simply logged
• Platform and modality fit — confirm genuine experience with your specific modality (small molecule, biologics, ATMP) rather than general facility capability
• Regulatory affairs resources — dedicated, in-house regulatory affairs capability signals better anticipation of evolving requirements than reliance on external consultants alone
• Financial and operational stability — a partner’s financial health directly affects their ability to sustain compliance investment over a multi-year program

Red Flags to Watch For

• Reluctance to share full inspection or Form 483 history
• Vague answers about CAPA closure timelines
• High, unexplained turnover in the quality unit
• Undisclosed subcontracting of critical steps
• Defensive responses to questions about past findings

5 Questions to Ask Shortlisted CDMOs

1. Can you share your facility’s full FDA Form 483 and warning letter history for the past five years?
2. What percentage of your CAPA actions close within their originally committed timeline?
3. How do you validate AI or automation tools used in GMP documentation, and what human review controls are in place?
4. What was your most recent technology transfer for a product of similar complexity to ours, and what challenges arose?
5. How is quality unit authority structured, and can the quality head halt production independent of commercial pressure?

Frequently Asked Questions (FAQ)

What is GMP in pharmaceutical manufacturing?

GMP is the regulatory framework requiring that pharmaceutical products be consistently produced and controlled according to defined quality standards, covering personnel, facilities, processes, documentation, and testing throughout the manufacturing lifecycle.

What is the difference between GMP and cGMP?

GMP refers to the baseline regulatory framework established by agencies such as the FDA, while current Good Manufacturing Practice (cGMP) emphasizes that manufacturers must continuously adopt current technologies and methods rather than relying on outdated systems. Both terms describe the same underlying regulatory expectations.

How do CDMOs achieve and maintain GMP certification?

CDMOs achieve certification through successful regulatory inspection by the relevant national authority, following demonstrated facility qualification, validated processes, and a functioning quality management system. Maintaining certification requires ongoing self-inspection, CAPA effectiveness, and passing periodic re-inspection cycles.

What happens during an FDA GMP inspection?

FDA investigators assess facility conditions, review batch records and documentation, evaluate laboratory controls and data integrity practices, and interview personnel. Findings are recorded on a Form 483, which is not a final ruling; if the company’s written response fails to adequately address major violations, FDA may escalate to a warning letter.

What are the most common GMP violations at CDMOs?

Laboratory controls and out-of-specification investigation failures remain the most frequently cited issues, alongside data integrity deficiencies such as audit trail gaps and process validation shortfalls, particularly around mature continued process verification programs, according to The GMP Consultant (2026).

How do I verify a CDMO’s GMP compliance status?

Request the facility’s current regulatory certificates directly from the CDMO, cross-reference FDA’s public warning letter database and compliance actions data dashboard, and ask for recent Form 483 responses and CAPA closure evidence rather than relying solely on the CDMO’s self-reported compliance status.